A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme

Glioblastoma Multiforme Clinical Trial

Official title:

Pharmacological Ascorbate Combined With Radiation and Temozolomide in Glioblastoma Multiforme: A Phase 2 Trial

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02344355
• Other study ID #: 201504786
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: March 13, 2017
• Est. completion date: December 2027

Study information

• Verified date: November 2023
• Source: University of Iowa
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This clinical trial evaluates adding high-dose ascorbate (vitamin C) to standard of care treatment of glioblastoma multiforme (a type of brain tumor) in adults. All subjects will receive high-dose ascorbate in addition to the standard treatment.

Description:

Standard treatment for glioblastoma multiforme (GBM) involves maximum safe surgical resection followed by radiation combined with temozolomide (a chemotherapy pill you take by mouth). After radiation, patients receive additional cycles of temozolomide (adjuvant chemotherapy).

Participants will:

• receive high doses of intravenous (IV) ascorbate three times a week during the combined radiation and chemotherapy phase

• receive high doses of intravenous (IV) ascorbate twice a week during adjuvant chemotherapy (after radiation)

• complete health-related quality of life questionnaires pre-radiation, 4 weeks into radiation, 4 weeks after radiation, and then every 3 months. In addition, patients will complete neurocognitive testing pre-radiation, 4 weeks into radiation, 4 weeks after radiation, and approximately 9 months after initiating radiation therapy.

The adjuvant chemotherapy portion of this study lasts for 6 months. After that is completed, participants will go back to standard therapy for their cancer. Participants will continue to have life-long follow-up for this study.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 90
• Est. completion date: December 2027
• Est. primary completion date: December 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Ability to understand and willingness to sign informed consent (power of attorney and/or legally authorized representatives cannot sign on behalf of the patient)

• Patients must have newly diagnosed (i.e., within 5 weeks), histologically or cytologically confirmed glioblastoma multiforme.

• Diagnosis must be made by surgical biopsy or excision.

• Therapy must begin = 5 weeks after surgery or biopsy

• Age = 18 years

• ECOG performance status 0-2. (KPS > 50)

• Absolute neutrophil count (ANC) = 1500 cells per mm3

• Platelets = 100,000 per mm3

• Hemoglobin = 8 g/dL

• Creatinine = 2.0 mg

• Total bilirubin = 1.5 mg/dL

• ALT = 3 times the institutional upper limit of normal

• AST = 3 times the institutional upper limit of normal

• Tolerate one test dose (15g) of ascorbate.

• Not pregnant.

Exclusion Criteria:

• Recurrent high grade glioma

• G6PD (glucose-6-phosphate dehydrogenase) deficiency.

• Patients actively receiving insulin or using a finger-stick glucometer daily for blood glucose measurements

• History of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide.

• Significant co-morbid central nervous system disease, including but not limited to, multiple sclerosis.

• Patients who are on the following drugs and cannot have a drug substitution: warfarin, flecainide, methadone, amphetamines, quinidine, and chlorpropamide.

• Known active concurrent malignancy, as determined by treating physicians.

• Patients who have received prior chemotherapy (including Gliadel wafers) for the current glioma.

• Prior radiation therapy to the head or neck resulting in overlap of RT fields.

• Patients receiving any other investigational agents (imaging agents are acceptable)

• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection that would result in a hospital stay or delay of treatment, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements or impact patient safety.

• Pregnant women.

• Breastfeeding women.

• Known HIV-positive individuals. High-dose ascorbate acid is a known CYP450 3A4 inducer, which results in lower serum levels of antiretroviral drugs.

Related Conditions & MeSH terms

• Glioblastoma
• Glioblastoma Multiforme

Intervention

Drug:
• Temozolomide
oral temozolomide (75 mg/m2), given 7 days per week, for a maximum of 49 days during radiation therapy. Starting 1 month after radiation therapy, additional temozolomide will be given as chemotherapy cycles. Each cycle is 28 days. For the first cycle, temozolomide will be administered (150 mg/m2) once per day for 5 days. If the subject tolerates the first cycle well, temozolomide will be prescribed at 200 mg/m2 for cycles 2 through 6. Each cycle is 28 days.

Radiation:
• radiation therapy
Conformal radiation administered daily, M-F, to a total dose of 61.2 Gray in 34 fractions.

Drug:
• Ascorbic Acid
Intravenous infusions of 87.5g of ascorbate administered three times weekly during radiation. After radiation, ascorbate is administered twice weekly through the end of cycle 6 of temozolomide.

Locations

Country	Name	City	State
United States	Holden Comprehensive Cancer Center	Iowa City	Iowa

Sponsors (4)

Lead Sponsor	Collaborator
Bryan Allen	Gateway for Cancer Research, Holden Comprehensive Cancer Center, National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

References & Publications (1)

Schoenfeld JD, Sibenaller ZA, Mapuskar KA, Wagner BA, Cramer-Morales KL, Furqan M, Sandhu S, Carlisle TL, Smith MC, Abu Hejleh T, Berg DJ, Zhang J, Keech J, Parekh KR, Bhatia S, Monga V, Bodeker KL, Ahmann L, Vollstedt S, Brown H, Shanahan Kauffman EP, Schall ME, Hohl RJ, Clamon GH, Greenlee JD, Howard MA, Schultz MK, Smith BJ, Riley DP, Domann FE, Cullen JJ, Buettner GR, Buatti JM, Spitz DR, Allen BG. O2·- and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate. Cancer Cell. 2017 Apr 10;31(4):487-500.e8. doi: 10.1016/j.ccell.2017.02.018. Epub 2017 Mar 30. Erratum In: Cancer Cell. 2017 Aug 14;32(2):268. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Health-related Quality of Life (HRQOL)	Measure health-related outcomes using the validated EORTC (European Organization for Research and Treatment of Cancer) questionnaires QLQ-C30 and BN-20.	monthly for 3 months, then every 3 months up to 5 years post treatment
Primary	Overall Survival (OS)	From radiation day 1 until date of death from any cause.	monthly up to 5 years post treatment
Secondary	Progression Free Survival (PFS)	From radiation day 1 to documented disease progression in MRI imaging as described by the RANO criteria	monthly up to 5 years post treatment
Secondary	Adverse Event Frequency	Categorize and quantify using the Common Terminology Criteria for Adverse Events (CTCAE) v. 4 from radiation day 1 through 7 months post-radiation.	monthly through 7 months post-radiation